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1. Introduction
As Alois Alzheimer himself first observed, the brain of an individual affected by Alzheimer's
disease (AD) shows aggregations of the peptide beta-amyloid (Aβ) and tau proteins, which
form characteristic plaques and neurofibrillary tangles respectively [1].
Since Aβ is known to participate in many normal body functions, its precipitation into plaques,
often referred to as ‘amyloid cascade’, has been for a long time the only recognized, yet
unexplained mechanism of AD pathogenesis [2]. In time, however, diverse phenomena, such
as oxidative stress, aberrant inflammations, impaired energy metabolism and more have been
gradually discovered to contribute to the cascade [3].
The observation that Aβ aggregation in plaques is an age-dependent phenomenon, whereas
Aβ production is not, suggested that some other age-dependent mechanism must play a role
in transforming Aβ into a neurotoxic element. The fact that some metals, such as copper and
zinc, are known to modulate glutamatergic neurotransmission [4] led researchers to hypothe‐
size that late-age abnormalities in the homeostasis of one or more transition metals may play
a role in the amyloid cascade.
Moreover, much evidence gathered on AD depicts an improperly functioning ceruloplasmin,
an enzyme synthesized by the liver, which controls iron oxidization state. There is also
evidence that a functional failure of systemic ceruloplasmin may be behind the iron-related
redox processes that produce oxidative stress in the AD brain [5, 6]. Ceruloplasmin is the
‘crosstalk’ factor linking copper to iron metabolism, thus its failure is very likely to be a major
actor in the dysfunctional metal metabolism affecting AD individuals. Aβ may gain toxicity
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upon some interaction with copper, in a process involving ceruloplasmin, even though the
molecular mechanism still remains elusive.
This notion was further supported by the fact that the Amyloid precursor protein (APP) was
discovered to possess selective copper binding sites, which mediate redox activities causing
precipitation of Aβ even at low concentrations [7]. Aβ itself has been reported to possess
selective high- and low-affinity metal-binding sites which, in normal conditions, bind equi‐
molar amounts of either copper or zinc but, in conditions of acidosis, see zinc completely
displaced by copper [8]. Thus, hyper-metallation was suggested to be the mechanism that gives
Aβ its redox properties, triggering redox cycles through production of H2O2 that lead to self-
oxidation of Aβ, formation of oligomers with diverse grades of complexity and finally to Aβ
precipitation into plaques (Figure 1) [4, 9].
Figure 1. Systemic Non-Cp-copper in AD passes through the Blood Brain Barrier and causes an imbalance of copper in
the brain. Here Non-Cp-copper can interact with physiological amyloid-β (Aβ), forming clusters of metal-toxic soluble
Aβ that evolve in diffuse amyloid and, finally, in toxic plaques. Non-Cp-Copper can also interact with reactive oxygen
species (ROS), which are responsible for lipid peroxidation in neuron membranes, protein oxidation, and cleavage of
DNA and RNA molecules.
Diverse animal studies support the toxic role of copper in AD pathogenesis.
White et al. [10] showed that the copper contents of both liver and cerebral cortex in APP−/−
and amyloid precursor-like protein (APLP2−/−) knockout mice were significantly increased,
supporting the authors’ hypothesis that the APP gene modulates hepatic and cortical copper
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levels. However, the mechanism leading to increased brain copper content (due to APP gene
knockout) remains known. Serum copper levels were not significantly more altered in APP−/−
and APLP2−/− mice than in wild-type mice. It appears that a failure of copper excretion from
the brain to the blood or, more likely, an imbalance of copper distribution between the Cp-
bound and unbound fractions could be associated with the deposition of excessive copper
levels in the brain in this knockout model. Besides demonstrating that the AβPP is an important
regulator of brain copper homeostasis, White et al. also demonstrated that it potentiates the
Aβ-mediated neurotoxicity by increasing oxidative stress.
Sparks and Schreurs [11] demonstrated that adding 0.12 ppm (0.12 mg/L) of copper to water
given to a cholesterol-fed rabbit AD-model resulted in significantly enhanced cognitive
waning and also exacerbated amyloid plaque deposition. This finding led to serious concerns
in some Government Environmental Agencies about the content of copper in drinking water
delivered to households via copper pipes. It must be kept in mind that cholesterol, though
vital for neuronal transmission, synaptic plasticity and cell function, is also a well-established
risk factor for atherosclerosis and AD [12]. Cholesterol to 7-hydroxy cholesterol oxidation,
caused by Aβ, is extremely toxic for neurons [13]. Cp levels measured using o-dianisidine
dihydrochloride as a substrate in the plasma of cholesterol-fed rabbit model after adding
copper to drinking water, suggest an increase, although the change did not reach statistical
significance. This suggests that a Non-Cp copper increase is a vehicle of copper within the
brain.
In a different investigation [14], Sparks reconfirmed this earlier finding, reporting that other
animal models, like spontaneously hyper-cholesterolemic Watanabe rabbits, cholesterol-fed
beagles and rabbits, and PS1 and APP transgenic mice showed considerably increased brain
levels of Aβ when given copper-rich (0.12 ppm) drinking water. Notably, non-cholesterol fed
PS1 and APP transgenic mice models of AD demonstrated significantly enhanced levels of
Aβ due to copper exposure via drinking water, demonstrating that the mouse model of AD
exhibits vulnerability to copper even in the absence of cholesterol in the diet. This observation
highlights the fact that both cholesterol and copper are separate causative factors whose
interaction further enhances the formation of Aβ plaques.
In another study [15], Lu at al. confirmed the findings of Sparks and colleagues’. The authors
demonstrated that Kunming strain mice fed with a high-cholesterol diet and distilled water
containing 0.21 ppm copper exhibited significantly increased level of APP mRNA, coupled
with the activation of caspase-3 in the brain, suggesting apoptosis mediated neurotoxicity.
Strikingly, copper also increased cholesterol-induced learning and memory impairment in
mice.
Moreover, it has been reported [16] that, in Sprague-Dawley rats, which underwent bilateral
common carotid artery occlusion (2VO) and were administered with 250 ppm copper con‐
taining water for 3 months, chronic copper toxicity exacerbated memory impairment induced
by 2VO coupled with an augmented expression of brain AβPP and β-site AβPP-cleaving
enzyme 1 (BACE1) at both mRNA and protein levels. However, these copper-aggravated
changes were ameliorated after copper was withdrawn from the drinking water.
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As a whole, these experimental animal models demonstrated the toxicity mediated by copper
in the AD cascade, showing that increased level of copper ingested with drinking water, or
more generally through the diet, affects AD neuropathology.
All this evidence has eventually led to the proposal of the so called Metal Hypothesis of AD
(Bush et al. 2008), which is based on the concept that it is the interaction of Aβ with specific
metals, especially copper, that actually drives the amyloid cascade and AD pathogenesis.
One question remained: how does copper actually reach the brain? In fact, we normally ingest
copper through the diet - via food, drinking water, beverage, supplements - and copper status
in the body is regulated by the balance between duodenal absorption (intestine) and biliary
excretion (liver). After crossing the intestinal lumen, copper is transported via portal circula‐
tion to the liver, where it is partly stored and partly redistributed to other organs. In the
hepatocyte, copper is incorporated into ceruloplasmin, whose dimensions don’t allow an easy
crossing of the blood-brain-barrier (BBB).
An answer to  the question came with the discovery that,  although the vast  majority  of
human copper circulates tightly bound to ceruloplasmin [17, 18], a faulty copper metabo‐
lism leads to the creation of a small pool of copper that goes into circulation loosely bound
to and constantly exchanged among albumin, α2 macroglobulin, peptides, amino acids and
other low-molecular-weight compounds. Due to the loose character of the bindings,  this
portion is normally referred to as Non Ceruloplasmin copper (Non–Cp copper). The key
difference between bound (to ceruloplasmin) and Non-Cp copper lies in the fact that the
low-molecular-weight  compounds  can  easily  cross  the  BBB  [18],  thus  carrying  Non-Cp
copper into the brain. There, copper can enter cycles of Haber-Weiss or Fenton reactions
producing ⋅OH,  against  which our  body has  no defenses  [19],  and generate  pleiotropic
effects on the amyloid cascade [3].
The metal hypothesis has also gained support from consistent reports of enhanced concentra‐
tions of labile copper in areas of the brain that are considered critical for AD [20].
There is by now a solid body of literature reporting in vitro [8, 21, 22], experimental (reviewed
in [23, 24]) and clinical evidence gathered over the last years which have shown that some
systemic abnormalities in copper metabolism are shared between the AD and the Wilson’s
disease (WD). Wilson’s disease is the paradigmatic disease of copper toxicosis or accumulation
[18]. Although much less severe than in WD, it has been shown that the increases in Non-Cp
copper correlate with some typical AD deficits, with the 'core' markers of AD in the cerebro‐
spinal fluid [25], a poor prognosis of the disease [26], and the conversion from Mild Cognitive
Impairment (MCI) to full dementia [27]. Meta-analyses have confirmed increased levels of total
copper and Non-Cp copper in general circulation of AD patients compared with healthy
control subjects [28-30]. A higher intake of copper in the diet was also associated with cognitive
decline or with an increase in overall mortality. Specifically, in the 'Chicago Health and Aging
Project' (3718 subjects followed from 1993 to 2002), a diet with a content of 2.75 mg / day of
copper on average, along with a high saturated and trans fat intake, has been proved to be
associated with cognitive decline, which was estimated to be equivalent to an extra nineteen
years of aging [31]. In the 'Iowa Women's Health Study' (38772 older women followed from
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1986 to 2008), the use of dietary supplements of copper has been shown to be associated with
a 18% increase in total mortality [32]. Recently, it was shown that the increase of copper in the
soil in 26 provinces and 3 municipal districts in China, between 1991 and 2000, is associated
with an increased AD-related mortality. In geographic areas with higher concentrations of
copper, the relative risk of AD-related death is 2.6 times higher than that in geographical areas
with a lower content copper in the soil [33].
Also results of a recently completed Phase II clinical trial, based on using metal attenuat‐
ing  complexing  compounds  or  Zinc  therapy  [34-37],  appear  to  support  the  notion  of  a
copper dysfunction in AD. The available evidence has now reached such a quantitative and
qualitative level that the notion of a copper-related phenotype in AD has now started to
be accepted [23]. This is a very important step, since many translational hypotheses may
develop from this notion,  in terms of both diagnostic  and prognostic  tools,  with impor‐
tant repercussions in terms of preventive and therapeutic approaches. However, most of
the literature dealing with the relationship between copper and AD focuses on local copper
abnormal distribution,  especially in those specific  areas of  the brain that  are considered
critical for the disease. Recently, this vision has started to appear limited. There is now a
bulk  of  evidence  suggesting  that  all  modifications  should be  viewed in  a  wider  frame‐
work  of  systemic,  rather  than  local,  metal  dishomeostasis.  This  concept  can  be  better
understood looking at recent studies of the link between the status of serum ceruloplas‐
min and AD clinical signs and/or Aβ markers in the CSF [23]. Torsdottir et al. [38] reported
a decrease in ceruloplasmin activity in AD patients. Lower levels of circulating ceruloplas‐
min in  AD patients  with  different  CSF markers  of  AD were  reported by Brewer’s  [39],
Arnal’s [40] and Kessler’s [41] groups. In 2008, our laboratory demonstrated a consistent
and measurable increase of apo-ceruloplasmin (a defective form of ceruloplasmin, lacking
copper and its ferroxidase activity) in the serum and CSF of AD patients [42, 43].
Since both WD and the early-onset form of AD are known to have a genetic origin determining
the hereditability of the disease, researchers have embarked in a wide range of studies in the
attempt to find genes that cause the late-onset AD or at least contribute to it via damaging
phenomena, such as oxidative stress, inflammation, apoptosis or an increased expression of
Aβ. In order to encompass as much as possible of the huge genome world, researchers have
also embarked in so-called large-scale genome-wide association studies (GWAS). These
studies search for DNA sequence variations that appear more common in individuals with a
certain disease than in individuals without that disease. GWAS typically analyze a multitude
of single gene variations, generally called single-nucleotide polymorphisms (SNPs), and verify
their association, if any, with the traits of a disease.
2. AD and APOE
So far, no specific gene has been found that can be reliably considered a cause of AD. Even
genes, whose mutations have been found responsible for early-onset AD, appear to have a
minor, or at least not a pivotal role in the late-onset form. However, numerous risk factors have
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been identified in the last few years. Historically, the first one to be established is the inheri‐
tance of the ε4 allele of the apolipoprotein E (APOE), found on chromosome 19. APOE is the
gene encoding the protein that carries cholesterol and other fats into circulation and manifests
itself in a number of alleles, of which ε2, ε3 and ε4 are the most common. The allele ε3, the
most common of the three, appears totally unrelated to the risk of developing AD. The slightly
less common ε4, instead, has been definitely established to increase the risk of developing AD.
The rare variant ε2 seems instead to provide some form of protection by delaying the onset
age of the disease.
Individuals inherit two copies of the APOE gene, one from each parent, which can be different
alleles. If one of the inherited alleles is ε4, the carrier has about a 3-fold increased risk of
developing AD. Two copies of ε4 make this risk is much higher, reaching a 15-fold increase of
the risk. In other words, it can be stated that APOEε4 carriers have a 90% statistical risk of
contracting AD if they are heterozygote and close to 100% if homozygote [44].
It must be emphasized, though, that we are dealing here with statistical risk: in fact, not all
individuals who have one or two ε4 develop AD and AD occurs also in people who have no
ε4. Thus, APOEε4 is a ‘susceptibility’ gene, i.e., a gene that affects risk but is not the cause.
3. Other genes
The fact that APOEε4 is neither necessary nor sufficient for the development of the disease has
supported the quest for more genetic risk factors and GWAS have led to the identification of
numerous genes now widely accepted as risk factors for AD. Major examples include:
CLU – The CLU gene on chromosome 8 encodes the protein clusterin, or apolipoprotein J,
which is implicated in multiple biological processes, such as lipid transport, membrane
recycling, cell adhesion and apoptosis. Two GWAS have independently found a statistical
association between a SNP within CLU and the risk of having AD [45, 46]. Despite the fact that
people who already have AD have more clusterin in their blood, and that clusterin blood levels
correlate with faster cognitive decline in individuals with AD, there is no indication that levels
of this protein can predict the onset of AD.
SORL1 – an APOE receptor in the neural system. Some variants on chromosome 11 have been
related to AD [47], since a significant decrease in their expression has been found in AD patients
and some authors have described a link between SORL1 and APP regulation.
CR1 – encodes the protein C3b/C4b receptor, whose deficiency may contribute to chronic
inflammation in the brain. Some specific variant of this gene have been identified as contrib‐
utors to AD [46, 47].
PICALM - located on chromosome 11, encodes phosphatidylinositol-binding clathrin assembly
protein, which is linked to the process by which brain nerve cells (neurons) communicate with
each other. GWAS have identified several functional SNPs in the PICALM gene [45-50]
In AD, GWAS have consistently shown that the effect size and the strength of association of
APOE variants are greater than the best of APOE-unrelated associations. This stresses the
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relevance of APOE as risk factor for AD, although also other explanations should be consid‐
ered: firstly, most GWAS do not study the variants’ true susceptibility but are rather based on
the identification of their tagging markers. The latter generally show much greater heteroge‐
neity than the former in terms of both alleles and extent of linkage. Consequently, it is possible
that some variants have in reality bigger effect sizes than the ones seen by GWAS. Secondly,
current GWAS platforms are often insufficient to detect rare variants. Thus, the existence of
some variants that have a big effect size but happen to be rare can remain undetected.
Moreover, the linear modeling framework often used in GWASs considers only one SNP at a
time, thus ignoring the genomic and environmental context of each SNP [51]. This is an
important limitation since the genotype-phenotype relationship is most likely characterized
by significant genetic heterogeneity and complex gene-gene and gene-environment interac‐
tions [52]. Recently, there has been a shift away from the ‘one SNP at a time’ method toward
a more holistic approach that includes the gene's environmental context.
Another approach is selecting a candidate gene on the basis of hypotheses regarding the
disease and then analyze all sequence changes of that gene. Direct sequencing has proven an
effective way to discover rare variants with large effect sizes. Recently, studies using next-
generation sequencing have led to the identification of rare frequency coding variants in PLD3
[53] and TREM2 genes [54, 55] associated with the risk of AD.
3.1. ATP7A and ATP7B
Two serious disorders are today recognized to be due to a dyshomeostasis in copper metab‐
olism: Menkes disease (MD) and Wilson’s disease (WD). Both are caused by a mutation of one
gene: ATP7A in MD and ATP7B in WD, which generate a dysfunction of the proteins they
encode: ATP7A and ATP7B, respectively [56]. These two proteins are copper pump proteins
or transporting ATPase and, although they have somewhat different distributions in diverse
cell types, both are key in regulating copper levels in the body.
The ATP7A gene is located on the long (q) arm of the X chromosome. The protein it encodes,
ATP7A, is found virtually everywhere in the body except in the liver and delivers copper
wherever it is needed within tissue cells. In the small intestine, it contributes to control the
absorption of copper from food. Mutations of the ATP7A gene lead to synthesis of dysfunc‐
tional proteins, of which some engage in disorderly copper transport while others are even
unable to bind the metal. More than 100 mutations the have been identified as causes of MD.
ATP7B is a gene of chromosome 13, expressed mainly in the liver, although it has also been
detected in the brain, heart, kidney, lung, mammary gland and placenta [57]. The protein it
encodes, ATP7B, maintains the body copper homeostasis. In the hepatocyte, ATP7B receives
copper from ATOX1 and it moves across the trans Golgi network where it incorporates this
metal into apo-ceruloplasmin generating a holo-active form. When intracellular copper levels
exceed cell needs, ATP7B moves toward the bile canaliculi and carries out the excretion of
copper [58].
Technically, mutations of the two genes have somewhat opposite effects: in MD, the dysfunc‐
tional ATP7A results in an unbalanced distribution of copper throughout the body. Copper
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accumulates in some tissues while it remains insufficient in others, where the decreased supply
reduces the activity of enzymes that are necessary for the health of numerous body parts, such
as bone, skin, blood vessels, and the nervous system. In WD, instead, the dysfunctional ATP7B
causes: (i) a failure in the incorporation of copper into the holo-ceruloplasmin, resulting in
increased levels of Non-Cp copper being released into the blood stream and in low circulating
levels of that protein; (ii) decreased levels of copper released into the bile canaliculi, causing
cell over-feeding and intracellular copper deposits, which accelerate apoptotic cell death [59].
We know that in WD huge amounts of Non-Cp copper enter the brain through the BBB, where
labile copper accumulates and leads to neurodegeneration. WD is considered the hallmark of
copper toxicosis.
Since increased copper levels characterizing WD are shared in a smaller scale by AD patients,
the ATP7B gene and its variations have of course become the focus of much of our research
focusing on copper. Some authors have expressed doubts about this research direction by
pointing out that neurodegeneration in WD leads to movement disorders with little or no effect
on cognition, while AD neurodegeneration affects chiefly cognition. Moreover, onset ages are
very different in the two pathologies as WD appears typically in childhood, whereas late-onset
AD by definition after 60-65y. In other words, even accepting the fact that the two pathologies
share copper toxicity, manifestations are so different that it seems unreasonable to claim that
the same gene causes both of them. In reply to this valid concern, other authors have argued
that ATP7B has a high variability. Thus, the possibility that this gene is a causative gene for
WD when in homozygosis and a susceptibility gene for AD (interacting with environmental
factors and other risk genes) cannot be ruled out. Other genes have shown unexpected diverse
effects. ATP7A, for example, which is causative of MD, has been recently recognized to be
associated with a mild form of occipital horn syndrome [60]. Moreover, recent evidence has
demonstrated that certain missense mutations of this gene can cause a syndrome restricted to
progressive distal motor neuropathy even without signs of copper deficiency [61].
Our laboratory has pursued the link between copper and AD pathogenesis on the assumption
that the excessive Non-Cp copper production in the body is actually due to a faulty ATP7B
causing a flaw in the incorporation of copper into nascent ceruloplasmin in the liver [56]. On
this basis, we have embarked in an extensive study of the ATP7B gene and of the protein
ATP7B, which is the only one known to catalyze that incorporation.
Unfortunately, analysis of the ATP7B gene is not an easy task, due to its huge variability. The
1000 Genomes project has identified 1,358 variations of ATP7B in human populations. At least
500 of them have been recognized as disease-causing [62]. Worldwide detection of ATP7B
mutations is actually difficult [63] since most mutations are rare, reported only within single
families and often prevalent in specific ethnic groups [32]. As a result, the database regarding
both the gene’s properties and the possible dysfunctions of the proteins they encode is still
largely insufficient [64].
The first significant information on the structure of the ATP7B protein was gained from a
homology modeling study [65]. Some more light was later shed by nuclear magnetic resonance
(NMR) spectroscopy studies [66-70]. Recently, significant progress in the comprehension of
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ATP7B structural organization has come from the solution of the crystal structure of the
bacterial copper ATPase LCopA [71]. The LCopA protein model has been employed as a
template to analyze ATP7B core domain on the basis of its sequence homology to build
interpretations of WD mutations [64].
We know that mutations leading to a complete abolition of ATP7B function, chiefly early stop
mutations and mutations in regions of the gene that have a high functional importance, lead
to an early and predominantly hepatic dysfunction. Conversely, point mutations in regions
that are functionally less important are associated with a later onset and predominantly
neurological or psychiatric dysfunctions [17].
An effective strategy to characterize genetic compositions, which has become popular in recent
years, is the so-called in-silico analysis, i.e., performed via computer simulations. Several
computational procedures have been developed to analyze the effects of genetic variants on
the protein function. The advantage of this type of analysis is that it allows analysis of huge
amounts of data, delivered by high-throughput sequencing technologies, in relatively short
time. These procedures take into account different factors associated with the protein proper‐
ties, such as chemistry constraints, three dimensional structure, and amino acid sequences of
homologous and orthologous proteins [72].
Our laboratory has used a new in-silico approach based on amino acid sequence, utilizing four
among the most used bioinformatics tools (i.e. Polyphen- 2, SIFT, Panther, and PhD-SNPs).
We have applied this approach to non-synonymous SNP (nsSNPs) detected in the ATP7B gene
to profile WD-causing and WD-non-causing mutations, while obtaining at the same time
useful information about the gene’s domains that could potentially harbor loci of susceptibility
for other disorders related to copper metabolism [73].
3.2. rs7323774 and rs2147363
In pursuit of the identification of regions in the ATP7B gene linked to copper dishomeostasis,
our laboratory has embarked in an investigation of the association between copper-related
biochemical markers in serum (bound copper, Non-Cp copper and ceruloplasmin) and
variants of the ATP7B gene.
In one study of 399 AD patients and 303 healthy elderly controls, we focused our attention on
a set of four SNPs that had been reported to be informative of the ATP7B gene structure [74]:
rs1801243 (missense substitution: Ser406Ala), rs2147363 (intronic variant: c.1544-53A>C),
rs1061472 (missense substitution: Lys832Arg) and rs732774 (missense substitution:
Arg952Lys). We had already found in a previous study that those SNPs among the four that
lay in the transmembrane domains appear to have an association with AD [75].
We first stratified the AD and control groups into three ‘classes’ according to their Non-Cp
copper levels: ‘low Non-Cp copper’ (<1 µmol/L), ‘medium Non-Cp copper’ (≥1, <1.6 µmol/L)
and ‘high Non-Cp copper’ (≥1.6 µmol/L) (Figure 2). Results showed antithetic distributions
for patients and controls: the ‘low Non-Cp copper’ class accounted for 27% of AD cases vs.
61% of controls; the ‘medium Non-Cp copper’ for 11% of AD vs. 10% of controls and the ‘high
Non-Cp copper’ for 62% of AD versus 29% of controls. The serum copper profile was then
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analyzed in relation to the selected gene variants in the sole ‘high Non-Cp copper’ class
(patients with AD, n = 109; controls, n = 53).
Figure 2. Stratification of the AD and control groups (CTRL) into three ‘classes’ according to their Non-Cp copper lev‐
els: ‘low Non-Cp copper’ (<1 µmol/L), ‘medium Non-Cp copper’ (≥1, <1.6 µmol/L) and ‘high Non-Cp copper’ (≥1.6
µmol/L). The bar graph reports the percentage of AD (first bar from left) and CTRL (second bar from left) for each
class.
The main result of this study was that individuals who are GG homozygous for ATP7B
rs7323774 SNP have higher levels of Non-Cp copper in their serum. This was true for the entire
sample of patients and controls but was definitely more pronounced in AD individuals. Non-
Cp copper distributions of AD patients turned out antithetic to those of controls and results
showed that this is due to those ATP7B variants that are located in regions encoding ATP7B
transmembrane domains, i.e., variants that we know to be associated with copper dyshomeo‐
stasis in AD. It must be noted, however, that we selected the variants on the basis of the
information they could deliver on the ATP7B gene structure, not for their impact on gene
function. Consequently, it is obvious that rs1801243, rs2147363, rs1061472 and rs732774, even
though significantly associated with AD [74], could not be the loci responsible for the effects
of the ATP7B gene on AD, either in terms of Non-Cp copper derangement or in terms of an
increased risk of the AD [76].
In another study of 286 AD patients and 283 controls we focused on the rs2147363 and
rs7334118 variants of the ATP7B gene. All genotype frequencies in our controls were within
the ranges reported previously in the European origin populations of the HapMap project
(available on http://hapmap.ncbi.nlm.nih.gov).
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We analyzed the genetic association between SNPs and AD risk. Our study revealed a
significant association between rs2147363 and AD. When data were adjusted for confounding
variables (i.e., age, gender, and APOE genotype), significant results were obtained for the
recessive model (OR: 1.63, 95% CI: 1.03–2.57; p = 0.035) and Log-additive model (OR: 1.51, 95%
CI: 1.05–2.16; p = 0.025).
In order to verify whether rs2147363 has any functional variants in LD, we also analyzed the
SNPs that showed a complete LD (D’ = 1) with this ATP7B variant in Tuscans in Italy (TSI),
which is the HapMap population most genetically related to our sample. We identified ten
SNPs in complete LD with the rs2147363. We prioritized these variants using FastSNP. This
analysis highlighted that one variant is a non-synonymous SNP (medium-high risk), four are
intronic enhancers (very low-low risk), four are intronic with no known function (no effect),
and one is a downstream variant with no known function (no effect) (Table 1).
SNP ID (rs) Possible Functional Effects Region SIFT PolyPhen2
rs7334118 Missense (non-conservative);Splicing regulation coding Damaging
Possibly
Damaging
rs4943053 Intronic enhancer intronic - -
rs9535803 Intronic enhancer intronic - -
rs9535809 Intronic enhancer intronic - -
rs2147362 Intronic enhancer intronic - -
rs11839458 Intronic with unknown function intronic - -
rs9526820 Intronic with unknown function intronic - -
rs9535827 Intronic with unknown function intronic - -
rs9535794 Downstream with unknown function 3-UTR - -
rs9535806 Intronic with unknown function intronic - -
Table 1. Prioritization and functional analysis of ATP7B SNPs in LD with rs2147363.
To predict the functional impact of the non-synonymous SNP (rs7334118), we used two
different bioinformatics tools: SIFT and Polyphen2. The application of both the SIFT algorithm
using orthologous sequences and the Polyphen2 tool highlighted that this coding variant may
have an adverse effect on the ATP7B protein.
To verify the hypothesis that genetic association of rs2147363 is due to LD with the rs7334118
SNP, 176 AD subjects and 169 healthy controls among the study population were genotyped
for the SNP rs7334118. Two AD patients were carriers of the rs7334118G allele, whereas no
healthy individual with this ATP7B mutation was identified. Even though this coding variant
was identified only in AD patients, its allele frequency in the AD group is in line with the minor
allele frequency observed in a general population of European origin (information available
at dbSNP). Thus, this result has to be confirmed in a bigger healthy control sample.
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To test whether the intronic region, in which rs2147363 is located, plays a role in the regulation
of the ATP7B gene function, the GERP++ and is-rSNP algorithms were used. rs2147363
nucleotide position resulted non-conserved, whereas, in the intronic region around this SNP,
7 nucleotide positions on the 16 analyzed (43%) achieve the GERP threshold [77]. Table 2
describes the findings of the is-rSNP algorithm. This analysis predicted the presence of binding
sites of 8 transcription factors (TF) binding sites, and, in two cases (i.e., Zfp423 and PLAG1),
the prediction results were significant (adjusted p < 0.05). The main result of this detailed
genetic analysis is that the significant association between rs2147363 SNP and AD can be
explained on the basis of the presence of TFs binding sites in the region in which this variant
is located. Thereby, rs2147363 may be associated with a cis-regulatory function. Specifically,
we observed two of the genetic models of rs2147363 SNP associated with AD: a recessive model
that suggested a 1.63-fold increased, and a log-additive model that suggested a 1.51-fold
increase in the risk of having AD. The Akaike Information Criterion (AIC) and Bayesian
Information Criterion (BIC) analyses highlighted that log-additive model achieved the most
reliable outcome. This suggests that C allele of rs2147363 SNP is additive: its presence in one
gene copy will lead to an increase in AD risk; its presence in both gene copies will lead to a
further increase. Additionally, we tested the reliability of our coding or noncoding hypotheses
to explain this intronic association. When we considered the coding hypothesis, we analyzed
the SNPs in complete LD (D' = 1) with rs2147363 in TSI. The functional prediction analysis
showed that the SNP rs7334118 has a complete LD (D’ = 1) with rs2147363. Moreover, rs7334118
has been recorded in the Wilson’s Disease Mutation database (available at http://www.wilson‐
disease.med. ualberta.ca) and in Human Genome Mutation Database (available at http://
www.hgmd.cf.ac.uk/) as a Wilson’s disease-causing variant, it corresponds to H1207R, located
into the P-domain, the domain in which phosphorylation of ATP7B occurs; in particular the
residue lies in the ATP-hinge which connects the nucleotide-binding domain (N-domain) and
the P-domain (Figure 3). Even though the genotype analysis in our case-control population
revealed the presence of two carriers of the rs7334118G allele in AD patients and none in
healthy controls, this ATP7B mutation could not alone explain the genetic association observed
for rs2147363. Specifically, two AD patients heterozygous for the rs7334118G mutation were
also carriers of the C allele in rs2147363 (1%). On the contrary, the other 166 AD patients,
carriers of the C allele in rs2147363, were negative for the rs7334118 WD mutation (99%).
However, this result does not exclude additional rare variants with large functional effects
may explain this intronic association.
We used the HapMap database to identify functional coding variants, in which only few
rare variants  are  present.  Using other  genomic databases,  such as  the database of  1,000
Genomes Project, may deliver new candidate variants that could be tested to explain our
intronic association. Conversely, in-silico analyses on rs2147363 revealed that this intronic
SNP  can  have  a  regulatory  role  on  ATP7B  function.  In  particular,  the  GERP  analysis
highlighted that the intronic region around rs2147363 resulted significantly conserved, and
the is-rSNP algorithm significantly predicted the presence of two TF-binding sites in the
rs2147363 region.  These  independent  findings  suggested that  this  genomic  region has  a
regulatory  function,  and  consequently  rs2147363  can  be  associated  with  clinical  pheno‐
types related to ATP7B dysfunction.
Alzheimer's Disease - Challenges for the Future84
Position Nucleotide GERP++ score
chr13: 52542783 C 2.17
chr13: 52542784 A 2.37
chr13: 52542785 G -7.84
chr13: 52542786 G 4.09
chr13: 52542787 G 0.889
chr13: 52542788 C -1.02
chr13: 52542789 C 1.93
chr13: 52542790 T -0.596
chr13: 52542791 C 4.11
chr13: 52542792 T -3.02
chr13: 52542793 A 2.98
chr13: 52542794 G -3.44
chr13: 52542795 G 2.55
chr13: 52542796 T -7.19
chr13: 52542797 T 3.25
chr13: 52542798 G 4.87
Table 2. GERP analysis of the genomic region around rs2147363. Conserved positions are highlighted in bold.
Specifically, Zfp423 and PLAG1 have been predicted to have a binding-site in the genetic
region of rs2147363. Both these TFs are involved in complex metabolic processes. For example,
Zfp423 has been reported to regulate neural and adipocyte development [78], whereas PLAG1
is a proto-oncogene that activates genes involved in uncontrolled cell proliferation (e.g., IGFII,
CRLF1, CRABP2, CRIP2, and PIGF) [79]. In this framework, our data on Zfp423 support the
hypothesis that ATP7B can be involved in molecular pathways linked to brain activity
regulation, suggesting new perspectives in the interpretation of neurologic signs of WD and
AD. This conclusion fits well with our original hypothesis that ATP7B can harbor variants that
may account for some of the missing hereditability of AD [80]. In particular, the present data
furnished a new insight into the copper hypothesis: non-coding regions can play a role in the
ATP7B function, and, thereby, genetic variation in ATP7B cis-regulatory elements within non-
coding regions may be associated with AD risk. Furthermore, genetic data adjusted for age
confounding effect confirmed the association between rs2147363 and AD risk. However,
although in-silico analyses support our hypothesis, further functional studies are necessary to
confirm the role of non-coding variants in the ATP7B gene function and in AD risk.
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Figure 3. Schematic representation of human ATP7B on the basis of homology-modeled structure [71]. The table re‐
ports the ATP7B SNPs studied from our group and the specific nucleotide and amino acid substitutions, standing in a
specific ATP7B domain.
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3.3. K832R (rs1061472) and R952K (rs732774)
In a recent study, we focused our attention on two functional changes in the ATP7B gene in
particular: K832R (rs1061472) and R952K (rs732774).
K832R corresponds to a non synonymous amino acid substitution and the corresponding
AAG>AGG mutation in exon 10 specifies this amino acid change in the A-domain, within the
ATP binding domain region of the protein. R952K (AGA>AAA) corresponds to a non-
synonymous substitution in the loop between Tm 5-Tm6 of the protein (Figure 3). Our aim
was to verify whether and in what way these amino acid changes have a disturbing effect on
the function of the ATP7B protein in terms of metal binding properties or ATP hydrolysis,
which can eventually result in copper dyshomeostasis.
We recruited 251 AD patients and 201 controls. As reported in the original article [76], for the
K832R substitution, the minor allele frequency (MAF) resulted 40% in Italian Tuscans, 45% in
Utah residents with Northern and Western European ancestry, while 42% in our controls. For
the R952K substitution, MAF was 39% in Italian Tuscans, 44% in Utah residents and 43% in
controls. The LD analysis revealed an association between K832R and R952K substitutions in
both AD patients (D’ = 0.79) and controls (D’ = 0.81). A high LD between K832R and R952K
was confirmed also in all HapMap populations.
Allele frequency distributions of both ATP7B SNPs differed between AD and controls: K832R
substitution genotype frequencies were K832/K832 10%, K832/R832 47%, and R832/R832 43%
(χ2 test, p = 0.022) in AD patients, while K832/K832 15%, K832/R832 54%, and R832/R832 31%
in our controls. R832/R832 genotype was more frequent in AD and this frequency variation
was maintained also when taking into account the Bonferroni correction (α= 0.025) as well as
in the logistic regression analysis, which took into account age and gender as confounding
factors. Our analysis revealed that patients with the ATP7B homozygous R832 genotype had
a 1.71-fold higher risk of developing AD than controls [adjusted OR= 1.71 (1.12–2.60); p = 0.012].
Genotype frequencies of the R952K substitution were R952/R952 15%, R952/K952 41%, and
K952/K952 45% in AD patients, and R952/R952 16%, R952/K952 54%, and K952/K952 30% in
our controls.
The χ2 test indicated that two distributions differed (p = 0.006) and the association between
the risk allele K952 and AD was maintained after checking for age and gender as possible
confounders in a logistic regression model. In summary, patients with the ATP7B homozygous
K952 genotype had a 1.82-fold increased risk of AD compared with controls [adjusted OR=
1.82 (1.19–2.80); p = 0.006].
We also performed a haplotype association analysis for the two SNPs in order to investigate
their combined effect on AD risk. The most common haplotype was R832/K952, which
contained a risk allele at each SNP locus. It was distributed as follows: 60.2% in AD patients
and 53.2% in controls (X2 = 4.85; p = 0.028).
The second more frequent haplotype was K832/R952, which contained no risk alleles and its
frequencies differed between the two cohorts, being 28.8% in patients and 37.3% in controls
(X2 = 7.21; p = 0.007).
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A logistic regression model was used to check these associations when taking into account age
as a possible confounder. The model confirmed the association (p = 0.018) and revealed that
the haplotype K832/R952 confers some protection against AD [adjusted OR= 0.68 (0.49–0.93)].
Thus, the haplotype association analysis revealed that the presence of alleles with normal
function, i.e., K832 and R952, is protective, even though the haplotype lies in a gene with
significant disease-risk.
It is important to notice that the SNPs of APOEε4 and ATP7B (both K832R and R952K) are
independent AD risk factors, as there was no difference in the frequency of the ATP7B alleles
between carriers and non-carriers of the APOEε4 variant (consistently p > 0.2), even when the
analysis was restricted to assessment of only the AD population (consistently p > 0.2). In
summary, the RR genotype in K832R raises the relative risk of developing AD by 71%, while
KK in R952K by 82%. The haplotype R832/K952, instead, appears to confer protection against
the disease by reducing the relative risk by 32%.These results seem in conflict with the fact that
GWASs carried out so far have never found an association between AD and the 13q14.3
chromosomal region where the ATP7B gene lies. However, we already described above how
GWAS, which are not well equipped to detect rare variants and fail to take into account the
genomic and environmental context of the investigated diseases, may underestimate ATP7B
haplotypes that are instead significantly associated with high risk of AD in individuals exposed
to inorganic copper [80].
4. Conclusions
The form of AD that has been the subject of this chapter accounts for about 95% of all AD cases
and appears rather late in life, normally after 60. For this reason it is called late-onset Alz‐
heimer's disease (LOAD), a term that well differentiates it from the inherited form, familial
AD, which is called early-onset AD because it develops much before 60 and accounts for the
remainder 5%. In opposition to familial AD, LOAD was initially called "sporadic" because early
researchers saw no link between the disease and hereditary factors and assumed that the
appearance of the disease was occasional and totally casual.
As we have seen above, this appeared untrue later, when researchers discovered the role of
several polymorphisms of the APOE gene in the disease pathogenesis. The term sporadic
continued to be widely used but we now know that LOAD is strongly influenced by both
genetic and environmental factors and appears to have a complex pattern of inheritance. It
remains true, however, that so far no gene has been found to be fully causative of LOAD, a
fact that is often referred to as missing heritability.
Due to the lack of a secure culprit, the role of genetic mutations in LOAD is often understated.
In an attempt to compensate, this chapter has described some of the most meaningful evidence
constituting the genetic background believed to provide a combined contribution to suscept‐
ibility (to become sick), which remains a statistical entity. It must be kept in mind that not only
genetic heterogeneity contributes to susceptibility but also other factors, such as reduced
penetration, a term describing that a predisposing genotype might be present without the
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pathology necessarily appearing, or even phenocopy, in which there are no predisposing
genotypes and yet the pathology develops due to environmental factors. The distinction
between genetic inheritance and genetic risk is fundamental and has helped understand how the
disease incidence can be decreased by changes in life style.
The chapter has also described GWAS, which have linked a substantial number of genes to the
pathogenesis of AD. It is important to notice that each gene, when taken alone, accounts only
for a small percentage of the disease incidence and often lacks clinical significance: the above
mentioned CLU gene, for example, has a proven correlation with AD-related cognitive decline
but its odds ratio tells us that it increases the risk of developing LOAD just 0.1-0.15 times.
Moreover, this gene has no clinical relevance since it does not predict the disease onset.
However, all the genetic evidence presented here should be regarded as the framework in
which systemic metal unbalances develop. For this reason, we have described in a consequen‐
tial but also factual fashion the role of systemic copper in the toxic processes leading to AD,
which we believe to be among the most important phenomena in AD pathogenesis.
We conclude with the introduction of an important, and somewhat innovative, notion
concerning copper in AD. We have shown how multiple variants of the APOE gene have an
actual effect on the statistical risk to develop AD and how they are also linked to level variations
of the portion of copper that does not bind to ceruloplasmin. These variants are also in linkage
disequilibrium with rare mutations, which can have a relevant effect on the risk of the disease.
We are now starting to explore this field by searching for multiple rare variants in the ATP7B
gene, which may account for portions of the odds of developing AD, defining a new gene for
AD susceptibility. Looking at all these associations as a whole, genetics appears as the factor
guiding the association between copper abnormalities and the clinical picture of the disease.
In other words, the fact that ATP7B multiple rare variants in practice modify the copper
homeostasis of an individual and have an effect on his/her risk of developing AD is an
expression of the causative character of this gene on the susceptibility of the disease.
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